$25.62-0.19 (-0.74%)
News25/Ratings9
Price$25.62-0.01 (-0.04%)
01:30 PM07:45 PM
News · 26 weeks48+100%
2025-11-022026-04-26
Mix2790d
- SEC Filings10(37%)
- Insider9(33%)
- Other6(22%)
- Earnings1(4%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form 424B3 filed by Evommune Inc.424B3 - Evommune, Inc. (0002044725) (Filer)
- SECSEC Form DEFA14A filed by Evommune Inc.DEFA14A - Evommune, Inc. (0002044725) (Filer)
- SECSEC Form DEF 14A filed by Evommune Inc.DEF 14A - Evommune, Inc. (0002044725) (Filer)
- INSIDERSEC Form 4 filed by Patel Jeegar Pravinkumar4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Drew Janice Suzann4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Bauer Eugene4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Carver Kyle4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Moss Gregory S.4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Pena Luis C.4 - Evommune, Inc. (0002044725) (Issuer)
- SECSEC Form S-1 filed by Evommune Inc.S-1 - Evommune, Inc. (0002044725) (Filer)
- SECEvommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- ANALYSTOppenheimer resumed coverage on Evommune with a new price targetOppenheimer resumed coverage of Evommune with a rating of Outperform and set a new price target of $50.00
- PREvommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in MigraineCompany to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to initiate in 3Q26 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET). The event will include presentations from members of Evommune's management team and the following two leading experts in migraine: Stewart
- SECSEC Form S-8 filed by Evommune Inc.S-8 - Evommune, Inc. (0002044725) (Filer)
- SECSEC Form 10-K filed by Evommune Inc.10-K - Evommune, Inc. (0002044725) (Filer)
- SECEvommune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- PREvommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively – Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Evommune Inc.SCHEDULE 13D/A - Evommune, Inc. (0002044725) (Subject)
- INSIDERDirector Lsp 7 Cooperative Ua was granted 358,680 shares (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERDirector Verduyn-Van Weegen Felice Isabel was granted 358,680 shares (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Evommune Inc.SCHEDULE 13D/A - Evommune, Inc. (0002044725) (Subject)
- INSIDERDirector Ra Capital Management, L.P. was granted 35,868 shares (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Evommune Inc.SCHEDULE 13G - Evommune, Inc. (0002044725) (Subject)
- SECEvommune Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- PREvommune Announces $125 Million Private PlacementEvommune, Inc. ("Evommune" or the "Company") (NYSE:EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $27.88. Evommune anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any transaction-related expenses. The private placement is expected to close on or about Feb